...
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx.
【24h】

Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx.

机译:对先前未治疗的口腔,口咽或下咽的晚期可切除鳞状细胞癌进行多模式强化治疗的长期结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Long-term disease control of an intensified treatment regimen for previously untreated stage III and IV resectable oral cavity, oropharyngeal, or hypopharyngeal squamous cell carcinoma was analyzed. METHODS: Forty-three patients with previously untreated, advanced stage, resectable squamous carcinomas of the oral cavity, oropharynx, or hypopharynx were enrolled in a prospective phase II institutional clinical trial at a tertiary care National Cancer Institute-designated comprehensive cancer center. It includes preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, and completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once-daily radiotherapy beginning on day 28 after surgery. RESULTS: Forty-three patients enrolled in the study. Protocol compliance was 53%. The range of time at risk was 10.4 to 56.23 months (median, 45 months). The locoregional (93%) and systemic (91%) disease control rates were excellent. Overall long-term survival was 79%. CONCLUSIONS: An intensive treatment regimen that improves compliance and long-term disease control is clearly feasible for this patient population.
机译:背景:对以前未治疗的III和IV期可切除口腔,口咽或下咽鳞状细胞癌的强化治疗方案的长期疾病控制进行了分析。方法:43例先前未经治疗,晚期,可切除的口腔鳞状癌,口咽或下咽癌患者在美国国家癌症研究所指定的三级医疗综合癌症中心接受了一项前瞻性II期机构临床试验。它包括术前加速超分割放疗并发顺铂,然后立即进行外科手术和术中放疗,并在术后早期每周一次紫杉醇,另外两个顺铂周期以及从术后28天开始的每天一次并发放疗完成。结果:43名患者参加了这项研究。协议符合率为53%。风险时间范围为10.4到56.23个月(中位数为45个月)。局部(93%)和全身(91%)的疾病控制率非常好。总体长期生存率为79%。结论:对于该患者群体,改善依从性和长期疾病控制的强化治疗方案显然是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号